title: Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.
abstract: OBJECTIVE
  To exploit the favorable dose intensity and safety profile of weekly paclitaxel, we conducted a Phase I trial of paclitaxel by 3-hour infusion in combination with estramustine phosphate (EM) in men with hormone-refractory prostate cancer (HRPC). The antimicrotubule drug combination of paclitaxel by 96-hour infusion plus EM is active in HRPC.
  
  
  METHODS
  Twenty-four patients with metastatic HRPC and progressive tumor after antiandrogen withdrawal were enrolled in this study. Oral EM was taken at a dose of 600 mg/m(2) daily for the initial 21 patients and on a reduced schedule of 280 mg twice daily for the final 3 patients. Paclitaxel was escalated from 60 to 118 mg/m(2).
  
  
  RESULTS
  The major toxicities were gastrointestinal and thromboembolic complications related to daily oral dosing of EM. Of the first 21 patients, one third (n = 7) discontinued therapy within 4 weeks because of protracted nausea and/or thrombotic complications. Dose-limiting toxicities at 118 mg/m(2) paclitaxel were fatigue and hepatotoxicity. Of 13 patients with measurable soft-tissue lesions, 6 had objective partial regressions, and 9 (37.5%) of 24 patients (95% confidence interval 19.1% to 59.1%) with elevated prostate-specific antigen levels had a 50% or greater decline of at least 4 weeks' duration.
  
  
  CONCLUSIONS
  Weekly paclitaxel at doses of 60 to 107 mg/m(2) were feasible in combination with oral EM, but daily oral EM produced unacceptable toxicity. On the basis of these results, a Phase II trial of weekly paclitaxel with the reduced dose and schedule of EM was initiated by the Eastern Cooperative Oncology Group to assess further the benefits and risks of this treatment in men with metastatic HRPC.
authors.affiliation: Departments of Medical Oncology and Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
authors.forename: N
authors.initials: N
authors.lastname: Haas
authors.forename: B
authors.initials: B
authors.lastname: Roth
authors.forename: C
authors.initials: C
authors.lastname: Garay
authors.forename: G
authors.initials: G
authors.lastname: Yeslow
authors.forename: M
authors.initials: M
authors.lastname: Entmacher
authors.forename: A
authors.initials: A
authors.lastname: Weinstein
authors.forename: A
authors.initials: A
authors.lastname: Rogatko
authors.forename: J
authors.initials: J
authors.lastname: Babb
authors.forename: C
authors.initials: C
authors.lastname: Minnitti
authors.forename: D
authors.initials: D
authors.lastname: Flinker
authors.forename: T
authors.initials: T
authors.lastname: Gillon
authors.forename: G
authors.initials: G
authors.lastname: Hudes
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000707:Anaphylaxis / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury; D018450:Disease Progression; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D004487:Edema / Q000139:chemically induced; D004961:Estramustine / Q000008:administration & dosage*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D007987:Gonadotropin-Releasing Hormone; D004961:Estramustine; D017239:Paclitaxel